Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD3ζ:MyD88 fusion protein
- Development stage
- Preclinical
- Lead developer
- University of Colorado Anschutz Medical Campus
- Modality
- Cell Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
CD3ζ:MyD88 fusion protein is a recombinant signaling construct designed for use in adoptive cell therapy (ACT), specifically for engineering tumor-infiltrating lymphocytes (TILs). The protein consists of the signaling domain of the CD3ζ chain, a critical component of the T-cell receptor (TCR) complex, fused to MyD88, a key adapter protein in the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) pathways. This fusion allows for the activation of MyD88-mediated costimulatory signals in a TCR-dependent manner upon antigen recognition. Developed by researchers at the University of Colorado Anschutz Medical Campus, the construct is intended to enhance T-cell expansion, persistence, and polyfunctionality while reducing exhaustion, thereby improving the efficacy of T-cell therapies against solid tumors such as melanoma.
- Other names
- CD3zeta:MyD88 fusion proteinCD3z:MyD88CD3ζ-MyD88
02
Targets
Myeloid differentiation primary response 88 (MyD88)–Interleukin-1 receptor-associated kinase (IRAK)–TNF receptor-associated factor 6 (TRAF6) signaling axisCD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CD3ζ:MyD88 fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD3ζ:MyD88 fusion protein.